Biomarin Pharmaceutical Inc’s filing revealed that its GVP, Chief Accounting Officer Burkhart Erin unloaded Company’s shares for reported $0.11 million on May 20 ’25. In the deal valued at $59.31 per share,1,786 shares were sold. As a result of this transaction, Burkhart Erin now holds 14,173 shares worth roughly $0.81 million.
Then, Burkhart Erin bought 1,786 shares, generating $105,928 in total proceeds.
Before that, Hubbard Cristin sold 273 shares. Biomarin Pharmaceutical Inc shares valued at $17,723 were divested by the EVP, Chief Commercial Officer at a price of $64.92 per share. As a result of the transaction, Hubbard Cristin now holds 32,700 shares, worth roughly $1.88 million.
Oppenheimer upgraded its Biomarin Pharmaceutical Inc [BMRN] rating to an Outperform from a a Perform in a research note published recently. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid November with a ‘”an Outperform”‘ rating. William Blair also remained covering BMRN and has decreased its forecast on October 30, 2024 with a “Mkt perform” recommendation from previously “an Outperform” rating.
Price Performance Review of BMRN
On Tuesday, Biomarin Pharmaceutical Inc [NASDAQ:BMRN] saw its stock jump 1.05% to $57.48. Over the last five days, the stock has gained 1.22%. Biomarin Pharmaceutical Inc shares have fallen nearly -12.55% since the year began. Nevertheless, the stocks have fallen -28.91% over the past one year.
How much short interest is there in Biomarin Pharmaceutical Inc?
A steep rise in short interest was recorded in Biomarin Pharmaceutical Inc stocks on 2025-05-30, dropping by -0.35 million shares to a total of 4.15 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 4.5 million shares. There was a decline of -8.49%, which implies that there is a negative sentiment for the stock.
